The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer.
Alberto Bardelli
No relevant relationships to disclose
Simona Corso
No relevant relationships to disclose
Andrea Bertotti
No relevant relationships to disclose
Sebastijan Hobor
No relevant relationships to disclose
Giulia Siravegna
No relevant relationships to disclose
Andrea Sartore-Bianchi
No relevant relationships to disclose
Giorgia Migliardi
No relevant relationships to disclose
Francesco Galimi
No relevant relationships to disclose
Calogero Lauricella
No relevant relationships to disclose
Carlo Zanon
No relevant relationships to disclose
Alessio Amatu
No relevant relationships to disclose
Marcello Gambacorta
No relevant relationships to disclose
Luis A. Diaz
Consultant or Advisory Role - Inostics; Personal Genome Diagnostics
Stock Ownership - Inostics; Personal Genome Diagnostics
Victor E. Velculescu
Consultant or Advisory Role - Inostics; Personal Genome Diagnostics
Stock Ownership - Inostics; Personal Genome Diagnostics
Mark Sausen
No relevant relationships to disclose
Paolo M. Comoglio
No relevant relationships to disclose
Livio Trusolino
No relevant relationships to disclose
Federica Di Nicolantonio
No relevant relationships to disclose
Silvia Giordano
No relevant relationships to disclose
Salvatore Siena
No relevant relationships to disclose